Skip to main content
OpenTrials
Completed

NCT Number: NCT02267135

Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis

This study will assess the efficacy and safety of secukinumab compared to placebo in adult patients who have moderate to severe scalp psoriasis that is poorly controlled by current psoriasis treatments.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Scalp Psoriasis Psoriasis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Novartis Investigative Site, Sacramento, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Chronic scalp psoriasis for at least the previous six months
  • Moderate to severe scalp psoriasis as defined by a PSSI score of ≥12 and 30% or higher of scalp surface area affected
  • Must be candidates for systemic therapy, which means having scalp psoriasis inadequately controlled by topical treatments (corticosteroids), and/or phototherapy, and/or previous systemic therapy.

Exclusion criteria

  • Forms of psoriasis other than chronic plaque
  • Drug-induced psoriasis (e.g., new onset or current exacerbation from β-blockers, calcium channel inhibitors)
  • Ongoing use of prohibited treatments (e.g., topical or systemic corticosteroids, UV therapy)
  • Prior exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL17A or IL-17RA receptors
  • Use of other investigational drugs within 30 days prior to study entry, or within a period of 5 half-lives of the investigational treatment, whichever is longer
  • Active, ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab
  • Active system infections (with the exception of the common cold) during the two weeks prior to starting study treatment
  • Other protocol-defined inclusion/exclusion criteria may apply

Treatment and study plan

secukinumab 300 mg

Biological

Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.

Other names: AIN457 300 mg

Placebo

Biological

Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.

Primary outcomes

  1. Psoriasis Scalp Severity Index 90 (PSSI 90)

    Time frame: 12 weeks

    PSSI 90 response (yes) at Week 12; PSSI 90 response means at least a 90% improvement in scalp psoriasis

    Percentage of participants with Psoriasis Scalp Severity Index 90 (PSSI 90) response of "yes"

Secondary outcomes

  1. Secondary: Investigator's Global Assessment Model 2011 (IGA Mod 2011) Score of 0 or 1 (Scalp Only)

    Time frame: 12 weeks

    IGA mod 2011 score of 0 or 1 (scalp only) response at Week 12 (non-responder imputation); IGA mod 2011 score of 0 means no sign of scalp psoriasis, and IGA score of 1 means almost no scalp psoriasis

  2. Change From Baseline in PSSI Score

    Time frame: 12 weeks

    Change from baseline in Psoriasis Scalp Severity Index (PSSI) score. PSSI score ranges from 0-72 with 72 being severe

  3. Psoriasis Scalp Severity Index 75 (PSSI 75) Response

    Time frame: 12 weeks

    PSSI 75 response (yes) at Week 12 (non-responder imputation); PSSI 75 response means at least a 75% improvement in scalp psoriasis

  4. Psoriasis Scalp Severity Index 100 (PSSI 100) Response

    Time frame: 12 weeks

    PSSI 100 response (yes) at Week 12 (non-responder imputation); PSSI 100 response means no sign of scalp psoriasis

  5. Time to 50% Reduction in PSSI Score up to Week 12

    Time frame: 12 weeks

    Time to 50% reduction in PSSI score up to week 12 was estimated for drug arm

    The median time to reduction was not estimable for placebo because a 50% reduction in PSSI score was not achieved by enough participants receiving placebo

  6. Psoriasis Area and Severity Index 75 (PASI 75)

    Time frame: 12 weeks

    PASI 75 response (yes) at Week 12 (non-responder imputation); PASI 75 response means at least a 75% improvement in body psoriasis

  7. Psoriasis Area and Severity Index 90 (PASI 90)

    Time frame: 12 weeks

    PASI 90 response (yes) at Week 12 (non-responder imputation); PASI 90 response means at least a 90% improvement in body psoriasis

  8. Psoriasis Area and Severity Index 100 (PASI 100)

    Time frame: 12 weeks

    PASI 100 response (yes) at Week 12 (non-responder imputation); PASI 100 response means no sign of body psoriasis

  9. Investigator's Global Assessment Model 2011 (GA Mod 2011) Score of 0 or 1 (Entire Body Including Scalp)

    Time frame: 12 weeks

    IGA mod 2011 score of 0 or 1 (entire body including scalp); IGA mod 2011 score of 0 means no sign of psoriasis, and IGA mod 2011 score of 1 means almost no psoriasis

  10. Change From Baseline in Subject Assessment of Pain

    Time frame: 12 weeks

    Change from baseline in the Subject Assessment of Pain

    Scale of 0-10 with 10 being the most painful

  11. Change From Baseline in Subject Assessment of Itching

    Time frame: 12 weeks

    Change from baseline in the Subject Assessment of Itching

    Scale of 0-10 with 10 being the most itchy

  12. Change From Baseline in Subject Assessment of Scaling (Scalp Only)

    Time frame: 12 weeks

    Change from baseline in the Subject Assessment of Scaling (scalp only)

    Scale of 0-10 with 10 being the most scaling

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis

Acronym: SCALP

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Oct 17, 2014
Registry last updated
Jan 5, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.